KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Treasury Shares: 2009-2024

Historic Treasury Shares for Novavax (NVAX) over the last 15 years, with Dec 2024 value amounting to $95.9 million.

  • Novavax's Treasury Shares rose 8.23% to $102.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.7 million, marking a year-over-year increase of 8.23%. This contributed to the annual value of $95.9 million for FY2024, which is 3.89% up from last year.
  • Per Novavax's latest filing, its Treasury Shares stood at $95.9 million for FY2024, which was up 3.89% from $92.3 million recorded in FY2023.
  • Novavax's Treasury Shares' 5-year high stood at $1.5 million during FY2024, with a 5-year trough of $396,626 in FY2020.
  • Its 3-year average for Treasury Shares is $1.1 million, with a median of $1.0 million in 2023.
  • Data for Novavax's Treasury Shares shows a peak YoY skyrocketed of 1,518.51% (in 2020) over the last 5 years.
  • Novavax's Treasury Shares (Yearly) stood at $41.8 million in 2020, then soared by 103.56% to $85.1 million in 2021, then rose by 6.53% to $90.7 million in 2022, then grew by 1.77% to $92.3 million in 2023, then grew by 3.89% to $95.9 million in 2024.